Similar to FTO inhibitors, METTL3 inhibitors have been produced and studied in recent years, and they will be a potent potential target to treat patients with hematological malignancies in the future, especially AML and chemoresistant CML. Here, FTO is linked to chronic myelogenous leukemia, BCR-ABL1 positive.